Expanded Access to Belantamab Mafodotin for People with Multiple Myeloma


Full Title

Expanded Access Program for Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody


The purpose of this study is to give people with multiple myeloma access to the drug belantamab mafodotin before it is approved by the U.S. Food and Drug Administration. Doctors will continue to study the safety of the drug and see whether is causes few or mild side effects.

Multiple myeloma cells have a protein on their surfaces called BCMA that healthy immune cells do not. This protein promotes cancer cell growth and survival. Belantamab mafodotin attaches to the BCMA protein, damaging myeloma cells and causing them to die. It is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that has come back or continued to grow and cannot be successfully treated with other multiple myeloma therapies.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Malin Hultcrantz at 646-608-3714.



Disease Status

Relapsed or Refractory